Table 2.
Dose (g/kg) | HGB (g/L) | RBC (1012/L) | PLT (109/L) | WBC (109/L) | LYM (%) | NEUT (%) | MONO (%) | EO (%) | BASO (%) |
---|---|---|---|---|---|---|---|---|---|
Male | |||||||||
4 | 153.2 ± 4.4 | 8.34 ± 0.37 | 907.6 ± 104.9 | 7.47 ± 0.97 | 77.2 ± 3.5 | 11.4 ± 1.6 | 10.38 ± 4.32 | 0.95 ± 0.33 | 0.09 ± 0.10 |
2 | 153.6 ± 3.4 | 8.78 ± 0.76 | 859.6 ± 83.7 | 7.56 ± 1.14 | 75.5 ± 3.3 | 10.9 ± 3.4 | 12.88 ± 4.15 | 0.66 ± 0.42 | 0.10 ± 0.11 |
1 | 153.4 ± 5.1 | 8.48 ± 0.58 | 853.7 ± 65.2 | 7.91 ± 0.96 | 76.8 ± 4.1 | 11.7 ± 4.8 | 10.70 ± 5.47 | 0.82 ± 0.51 | 0.07 ± 0.08 |
Control | 152.8 ± 5.0 | 8.60 ± 0.47 | 877.8 ± 107.1 | 7.73 ± 1.08 | 78.5 ± 2.1 | 10.4 ± 2.2 | 10.15 ± 3.05 | 0.85 ± 0.41 | 0.08 ± 0.09 |
| |||||||||
Female | |||||||||
4 | 155.5 ± 3.3 | 8.46 ± 0.43 | 854.8 ± 104.5 | 7.84 ± 0.82 | 77.6 ± 4.4 | 11.7 ± 3.4 | 9.58 ± 3.92 | 0.98 ± 0.44 | 0.10 ± 0.09 |
2 | 154.2 ± 5.6 | 8.60 ± 0.51 | 826.3 ± 127.8 | 7.95 ± 1.14 | 76.5 ± 3.8 | 10.7 ± 5.4 | 11.96 ± 8.26 | 0.74 ± 0.55 | 0.08 ± 0.09 |
1 | 151.8 ± 3.9 | 8.35 ± 0.38 | 826.9 ± 79.1 | 7.40 ± 1.21 | 77.8 ± 2.9 | 10.8 ± 3.4 | 10.33 ± 3.80 | 0.94 ± 0.73 | 0.07 ± 0.08 |
Control | 153.9 ± 6.0 | 8.61 ± 0.53 | 833.1 ± 73.4 | 7.73 ± 0.80 | 78.4 ± 5.4 | 11.7 ± 3.0 | 8.85 ± 4.81 | 0.95 ± 0.32 | 0.08 ± 0.09 |
Note: values represent mean ± standard deviation (n = 10). HGB, hemoglobin concentration; RBC, red blood cell count; PLT, platelet count; WBC, white blood cell count; LYM, percent of lymphocytes; NEUT, percent of neutrophils; MONO, percent of monocytes; EO, percent of eosinophils; BASO, percent of basophils. Values of the treatment groups did not differ statistically from the control according to one-way ANOVA at p < 0.05.